Facebook
Twitter
LinkedIn
ForwardAcute Liver Failure: Science and Practice (RP2205B)
Registration will close at 9 am Friday 5/13
Acute liver failure (ALF) is a rare but devastating condition that arises from diverse etiologies, has a high mortality and requires high resource utilization including transplantation. The Acute Liver Failure Study Group (ALFSG) has been funded by the National Institutes of Health (NIDDK) since 1997 to collect detailed clinical data on more than 3,500 ALF patients and closed its registry, database and bio-repository permanently in 2019. This is an opportune time to take stock, consider where the field of study of liver failure is going, what has been accomplished and to determine future directions of research in this unique syndrome. The audience would include basic scientists that work on liver injury as well as clinicians (hepatologists, surgeons) who care for these very ill patients.
This two-day program will provide a comprehensive review of all aspects of the pathogenesis and treatment of ALF including possible future therapies. The initial day of the meeting will be devoted to presenting work pertaining to pathogenesis, epidemiology and patient evaluation. The second day of the meeting will be devoted to reviewing further aspects of disease management: ICU management, treatment and consideration of prognosis, liver transplantation and liver support devices.
Interested in Exhibiting?
Click here to view the Exhibitor Registration Information Page
This course/program is endorsed by AASLD. The Acute Liver Failure Study Group is pleased to have received the endorsement of the American Association for the Study of Liver Diseases (AASLD). Copyright © 2022 by the American Association for the Study of Liver Diseases. All rights reserved.
DISCLAIMER
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Target Audience
THIS ACTIVITY IS INTENDED FOR PROVIDERS AND RESEARCHERS IN THE SPECIALTIES OF:
- Gastroenterology and Hepatology
- Critical Care Medicine
- Surgery
- Anesthesiology
Learning Objectives
- Describe the differences between liver injury from acetaminophen (APAP) vs. other drugs.
- Restate the role of cytokines in relation to injury evolution
- Explain basic factors that promote liver regeneration.
- Discuss different mechanisms of liver injury and the role of genomics in susceptibility to acute liver failure.
- Describe the current state of genome wide association studies.
- Review current state of identification of single nucleotide polymorphisms (SNPs) for specific diseases/drug injuries
- Review the elements of the basic and advanced work-ups for ALF patients.
- Identify natural history, differences in presentation, and how etiology drives prognosis and transplant decisions.
- Describe the circulatory and neurological physiology of ALF.
- Explain new understanding regarding hemostasis in ALF, management of kidney injury and hemostasis
- Compare present treatment modalities and propose possible future management protocols.
- Contrast the differences in presentation and outcome of different etiologies.
- Relate how etiology drives prognosis and transplant decisions.
- Envision novel approaches to managing ALF in the future.
- Describe current issues surrounding liver support devices.
AGENDA
Acute Liver Failure: Science and Practice, a symposium.
Monday May 16, 2022
Session 1: Acute Liver Failure: Overview and Mechanisms of Liver Injury
Moderators: Brendan McGuire, MD (UAB) and William M. Lee, MD (UTSW)
Time | Presentation Title | Speaker |
8:00 - 8:05 am | Welcome to UTSW from the University President | Daniel Podolsky, MD |
8:05 - 8:10 am | Introduction to the Meeting | Brendan McGuire, MD |
8:10 - 8:35 am | Acute Liver Failure and ALFSG | William M. Lee, MD |
8:35 - 9:00 am | Mechanisms of Liver Injury | Lily Dara, MD |
9:00 - 9:20 am | Clinical Phenotypes of ALF | Raj Reddy, MD |
9:20 - 9:40 am | Acetaminophen Liver Injury: Current status * This presentation is not approved for AMA PRA Category 1™ credit | Laura James, MD, PhD |
9:40 - 10:00 am | Histopathology of ALF | David Kleiner, MD |
10:00 - 10:15 am | Discussion | |
Break
Session 2: Liver Regeneration and Response to Injury
Moderators: Adrian Reuben, MD (MUSC) and David Kleiner, MD (NCI)
Time | Presentation Title | Speaker |
10:30 - 10:50 am | Overview of Basic Regenerative Mechanisms | Sanjeev Gupta, MD |
10:50 - 11:15 am | Immunologic Basis of Liver Injury/Response | Evangelos Triantafyllou MD |
11:15 - 11:35 am | Wnt Signaling and Regeneration | Udayan Apte, PhD |
11:35 - 11:55 pm | Pathophysiology of cerebral edema | Chris Rose, PhD |
11:55 - 12:15 pm | Discussion |
|
Lunch Break – Visit Posters
Session 3: Genomics and Viral Discovery
Moderators: Jorge Rakela, MD (Mayo Clinic) and Tony Bass, MD (UCSF)
Time | Presentation Title | Speaker |
1:10 - 1:30 pm | Viral Discovery in ALF | Charles Chiu, MD |
1:30 - 1:50 pm | Genomics and Viral Liver Injury | Emmanuel Jouanguy, MD |
1:50 - 2:10 pm | Genomics of Drug-Induced Liver Injury * This presentation is not approved for AMA PRA Category 1™ credit | Paola Nicoletti, PhD |
2:10 - 2:30 pm | Biomarkers in ALF | Jorge Rakela, MD |
2:30 - 2:45 pm | Discussion |
|
Break
Session 4: Diagnosis, Evaluation and Prognosis of ALF
Moderators: Bob Fontana, MD (Michigan) and Dan Ganger, MD (Northwestern)
Time | Presentation Title | Speaker |
3:00 - 3:20 pm | Natural History of ALF | Adrian Reuben, MBBS |
3:20 - 3:40 pm | Causality: Determining Etiology in ALF | Daniel Ganger, MD |
3:40 - 4:10 pm | Prognostic Indices: Determining Outcomes | David Koch, MD |
4:10 - 4:30 pm | Methacetin Breath Test/Other Prognostic Tools | Robert J. Fontana, MD |
4:30 - 4:50 pm | Discussion |
|
Tuesday May 17, 2022
Session 5: Complications of ALF: Riding Out the Storm
Moderators: Iris Liou, MD (Univ. of Washington) and Bilal Hameed, MD (UCSF)
Time | Presentation Title | Speaker |
8:00 - 8:30 am | Critical Care of ALF: Overview | Dean Karvellas, MD |
8:30 - 8:50 am | Hemostasis in ALF: Is There a Coagulopathy? | Todd Stravitz, MD |
8:50 - 9:10 am | The Decision to List for Transplant | Shannan Tujios, MD |
9:10 - 9:30 am | Outcomes of Transplantation: SRTR/ALFSG | Dean Karvellas, MD |
9:30 - 9:45 am | Discussion |
|
Break
Session 6: Liver Support, Transplantation and The Future
Moderator: Anne Larson, MD (Univ. of Washington) and William M. Lee, MD (UTSW)
Time | Presentation Title | Speaker |
10:00 - 10:20 am | Liver support machines: Current status | Scott Nyberg, MD |
10:20 - 10:40 am | Clinical trial of biologics for liver regeneration | Russell Wesson, MD |
10:40 - 11:00 am | Pediatric ALF: Current Status | Jim Squires, MD |
11:00 - 11:20 am | Is ALF Going Away? An Epidemiologist’s View | Babak Orandi, MD |
11:20 - 11:40 am | New agents for liver recovery | Lars Zender, MD |
11:40 - 11:55 am | Discussion |
|
11:55 - 12:00 pm | Final Words | William M. Lee, MD |
PARKING
- UTSW Faculty and staff should park in their designated locations, and utilize campus transportation where needed.
- Visitors driving to campus may utilize a provided valet service at 6000 Harry Hines Blvd., Dallas, TX 75390 from 7:15 am to 5:15 pm on Monday and 7:30 to 12:15 on Tuesday.
- Extremely limited self parking is available for a fee in a visitor parking garage at 6001 Forest Park Rd.
The Excellence In Education Foundation Auditorium is located on the 2nd floor in the Simmons Biomedical Research Building (NB) at 6000 Harry Hines Blvd., Dallas, TX 75390.
Travel
BEFORE YOU COME
Stay at home if:
- You feel sick
- You have COVID-19 related symptoms
- You have a mild cough or low-grade fever (100° F/137.7° C or higher)
As a courtesy, please email us at [email protected] should you not be able to attend the conference in person.
The University of Texas Southwestern Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Texas Southwestern Medical Center designates this live activity for a maximum of 10.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This course/program is endorsed by AASLD. The Acute Liver Failure Study Group is pleased to have received the endorsement of the American Association for the Study of Liver Diseases (AASLD). Copyright © 2022 by the American Association for the Study of Liver Diseases. All rights reserved.
DISCLAIMER
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Available Credit
- 10.25 AMA
- 10.25 Attendance
Price
REGISTRATION
- Physicians and General Registration $100
- Trainees $50
- Full-time UTSW Faculty and Staff ONLY - Complimentary
To register:
- Create an account in EthosCE, online learning management system, by selecting the "create an account" link at the bottom of the page or "log-in" to your existing account.
- Return to this course page, click "Register" tab, and select the designated fee.
- In the following "checkout" pages you will verify and process your payment.
- After registration is completed, a confirmation will be sent by email.
Refund Policy:
A $25 handling fee will be deducted from cancellation refunds. Refund requests must be received by email at [email protected] by May 6, 2022. No refunds will be made thereafter.
BEFORE YOU COME
Stay at home if:
- You feel sick
- You have COVID-19 related symptoms
- You have a mild cough or low-grade fever (100° F/137.7° C or higher)
As a courtesy, please email us at [email protected] should you not be able to attend the conference.